{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:00:35Z","timestamp":1768554035023,"version":"3.49.0"},"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2011,2,3]],"date-time":"2011-02-03T00:00:00Z","timestamp":1296691200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1001072","type":"journal-article","created":{"date-parts":[[2011,2,3]],"date-time":"2011-02-03T21:37:27Z","timestamp":1296769047000},"page":"e1001072","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy"],"prefix":"10.1371","volume":"7","author":[{"given":"Sheeja M.","family":"Krishnan","sequence":"first","affiliation":[]},{"given":"Narendra M.","family":"Dixit","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2011,2,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C.","volume":"29","author":"D Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: An update.","volume":"49","author":"MG Ghany","year":"2009","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0168-8278(96)80225-X","article-title":"Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.","volume":"25","author":"G Dusheiko","year":"1996","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.510260231","article-title":"Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial.","volume":"26","author":"HC Bodenheimer","year":"1997","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1365-2893.1998.00099.x","article-title":"Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients.","volume":"5","author":"F Zoulim","year":"1998","journal-title":"J Viral Hepat"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1053\/j.gastro.2003.12.002","article-title":"Antiviral action of ribavirin in chronic hepatitis C.","volume":"126","author":"JM Pawlotsky","year":"2004","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"MP Manns","year":"2001","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"MW Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.","volume":"339","author":"JG McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(97)06088-1","article-title":"Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C.","volume":"351","author":"O Reichard","year":"1998","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.","volume":"352","author":"T Poynard","year":"1998","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage.","volume":"31","author":"LD Franceschi","year":"2000","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"s315","DOI":"10.1086\/376911","article-title":"Anemia in the treatment of hepatitis C virus Infection.","volume":"37","author":"MS Sulkowski","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2006.10.008","article-title":"Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a\/ribavirin treatment.","volume":"5","author":"KR Reddy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.","volume":"11","author":"MS Sulkowski","year":"2004","journal-title":"J Viral Hepat"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jhep.2008.11.006","article-title":"Ribavirin: Current role in the optimal clinical management of chronic hepatitis C.","volume":"50","author":"KR Reddy","year":"2009","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.","volume":"360","author":"C Hazode","year":"2009","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2010.02.003","article-title":"Development of novel therapies for hepatitis C.","volume":"86","author":"SM Lemon","year":"2010","journal-title":"Antivir Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ncpgasthep1274","article-title":"Interferon-based therapy for chronic hepatitis C: current and future perspectives.","volume":"5","author":"S Zeuzem","year":"2008","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/14656560903580001","article-title":"Role of ribavirin in HCV treatment response: now and in the future.","volume":"11","author":"MK Jain","year":"2010","journal-title":"Expert Opin Pharmaco"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11901-009-0007-9","article-title":"Optimizing peginterferon and ribavirin administration in difficult-to-treat patient populations.","volume":"8","author":"C Landaverde","year":"2009","journal-title":"Curr Hepatitis Rep"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/jac\/dkn421","article-title":"Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.","volume":"62","author":"J Morello","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/gut.2004.057893","article-title":"Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens.","volume":"54","author":"M Schmid","year":"2005","journal-title":"Gut"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00003088-200544040-00006","article-title":"Pharmacokinetic\/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.","volume":"44","author":"M Tod","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.mbs.2010.02.005","article-title":"Evaluating treatment of hepatitis C for hemolytic anemia management.","volume":"225","author":"S DebRoy","year":"2010","journal-title":"Math Biosci"},{"key":"ref26","first-page":"2491","article-title":"Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.","volume":"98","author":"DT Dieterich","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"ref27","first-page":"1302","article-title":"Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.","volume":"126","author":"NH Afdhal","year":"2004","journal-title":"Gastroenterology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.21409","article-title":"Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.","volume":"44","author":"RAD Rio","year":"2006","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1111\/j.1572-0241.2006.00774.x","article-title":"Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy.","volume":"101","author":"M Homoncik","year":"2006","journal-title":"Amer J Gastroenterol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep.21712","article-title":"Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.","volume":"46","author":"ML Shiffman","year":"2007","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jmv.21657","article-title":"Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response.","volume":"82","author":"F Falasca","year":"2010","journal-title":"J Med Virol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C.","volume":"436","author":"JJ Feld","year":"2005","journal-title":"Nature"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virusres.2004.11.006","article-title":"Metabolism and antiviral activity of ribavirin.","volume":"107","author":"WB Parker","year":"2005","journal-title":"Virus Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s00018-005-5455-y","article-title":"The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus.","volume":"63","author":"NM Dixit","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.","volume":"282","author":"AU Neumann","year":"1998","journal-title":"Science"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/jhep.2003.50218","article-title":"Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.","volume":"37","author":"E Herrmann","year":"2003","journal-title":"Hepatology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/135965350300800602","article-title":"Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase.","volume":"8","author":"P Colombatto","year":"2003","journal-title":"Antivir Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.","volume":"432","author":"NM Dixit","year":"2004","journal-title":"Nature"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/hep.21657","article-title":"Triphasic decline of hepatitis C virus RNA during antiviral therapy.","volume":"46","author":"H Dahari","year":"2007","journal-title":"Hepatology"},{"key":"ref40","first-page":"37","article-title":"Advances in the mathematical modelling of hepatitis C virus dynamics.","volume":"88","author":"NM Dixit","year":"2008","journal-title":"J Indian I Sci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus.","volume":"2","author":"L Rong","year":"2010","journal-title":"Sci Transl Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1615\/CritRevImmunol.v30.i2.30","article-title":"Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.","volume":"30","author":"L Rong","year":"2010","journal-title":"Crit Rev Immunol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0168-8278(01)00029-0","article-title":"Factors influencing ribavirin-induced hemolysis.","volume":"34","author":"HV Vlierberghe","year":"2001","journal-title":"J Hepatol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00535-003-1363-9","article-title":"Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.","volume":"39","author":"S Takaki","year":"2004","journal-title":"J Gastroenterol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1572-0241.2005.40757.x","article-title":"Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon\/ribavirin.","volume":"100","author":"V Balan","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000090942","article-title":"Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy.","volume":"76","author":"J Donnerer","year":"2006","journal-title":"Pharmacology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hepres.2005.10.003","article-title":"Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy.","volume":"34","author":"Y Inoue","year":"2006","journal-title":"Hepatol Res"},{"key":"ref48","first-page":"17","article-title":"The clinical pharmacology of ribavirin.","volume":"19","author":"P Glue","year":"1999","journal-title":"Semin Liv Dis"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.trsl.2009.04.002","article-title":"Estimation of red blood cell lifespan from alveolar carbon monoxide measurements.","volume":"154","author":"SM Krishnan","year":"2009","journal-title":"Transl Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ajh.20069","article-title":"Use of alveolar carbon monoxide to measure the effect of ribavirin on red blood cell survival.","volume":"76","author":"MA Virtue","year":"2004","journal-title":"Am J Hematol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.","volume":"464","author":"J Fellay","year":"2010","journal-title":"Nature"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1128\/AAC.43.10.2451","article-title":"Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.","volume":"43","author":"SL Preston","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/jpet.108.145854","article-title":"The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-\/- mouse erythrocytes.","volume":"329","author":"CJ Endres","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1572-0241.2007.01139.x","article-title":"Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.","volume":"102","author":"JG McHutchison","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350300800108","article-title":"Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anemia.","volume":"8","author":"ED Mangoni","year":"2003","journal-title":"Antivir Ther"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/jhep.2000.16661","article-title":"A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C.","volume":"32","author":"P Glue","year":"2000","journal-title":"Hepatology"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/sj.bjp.0701775","article-title":"Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters.","volume":"123","author":"SM Jarvis","year":"1998","journal-title":"Br J Pharmacol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(00)02249-2","article-title":"The blood in systemic disorders.","volume":"355","author":"JL Spivak","year":"2000","journal-title":"Lancet"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/jtbi.1997.0537","article-title":"Hematopoietic model with moving boundary condition and state dependent delay: applications in erythropoiesis.","volume":"190","author":"JM Mahaffy","year":"1998","journal-title":"J Theor Biol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1023\/A:1020797110836","article-title":"An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia.","volume":"19","author":"P Veng-Pederson","year":"2002","journal-title":"Pharm Res"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jtbi.2005.03.033","article-title":"A mathematical model of hematopoiesis\u2013I. Periodic chronic myelogenous leukemia.","volume":"237","author":"C Colijn","year":"2005","journal-title":"J Theor Biol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.moh.0000231418.08031.48","article-title":"Quantitative stem cell biology: computational studies in the hematopoietic system.","volume":"13","author":"I Roeder","year":"2006","journal-title":"Curr Opin Hematol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jtbi.2007.09.041","article-title":"Adding self-renewal in committed erythroid progenitors improves the biological relevance of a mathematical model of erythropoiesis.","volume":"250","author":"F Crauste","year":"2008","journal-title":"J Theor Biol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10928-008-9092-6","article-title":"Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.","volume":"35","author":"W Krzyzanski","year":"2008","journal-title":"J Pharmacokinet Phar"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"e1000416","DOI":"10.1371\/journal.pcbi.1000416","article-title":"Quantitative analysis of mechanisms that govern red blood cell age structure and dynamics during anaemia.","volume":"5","author":"NJ Savill","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"ref66","first-page":"364","article-title":"Bilirubin production as a measure of red-cell life-span.","volume":"79","author":"PD Berk","year":"1972","journal-title":"J Lab Clin Med"},{"key":"ref67","article-title":"Hematology.","author":"WS Beck","year":"1991"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1001072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T03:09:06Z","timestamp":1685934546000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1001072"}},"subtitle":[],"editor":[{"given":"Rustom","family":"Antia","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2011,2,3]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1001072","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,3]]}}}